drugset / Trial / NCT02626338

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

NCT02626338

Phase 1/2 Completed 16 enrolled Arog Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.

Timeline

Start
2016-02
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Crenolanib Small molecule
Background Cytarabine Small molecule
Background Etoposide Small molecule
Background Fludarabine Small molecule
Background G-CSF Unknown
Background Idarubicin Small molecule
Background Mitoxantrone Small molecule